Using ctDNA to Determine Therapies for Lung Cancer

This is a study to look at whether the presence of circulating tumour DNA (ctDNA) in the blood can help to predict whether giving adjuvant treatment after surgery can decrease the chance of the cancer coming back in people with lung cancer.

Trial Details

NCT ID
NCT04966663
Phase
PHASE2
Sponsor
University Health Network, Toronto
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Nivolumab
  • Pemetrexed
  • Gemcitabine
  • Cisplatin
  • Carboplatin
  • ctDNA blood test
Locations (sample)
  • Toronto, Ontario, Canada|43.70643,-79.39864

Key Eligibility Criteria

  • Age ≥ 18 years at the time of screening
  • Written informed consent obtained from the subject prior to performing any protocol-related procedures
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Weight ≥ 35 kg

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →